Company · founded 2013
Spero Therapeutics (United States)
Cambridge, United States · sperotherapeutics.com
- Citations, last 5 years
- 481
- Works, last 5 years
- 52
- h-index
- 51
- Scientists listed
- 7
- Grants since 2016
- 13
Grants received
2021–2025 · contract · N01
Advanced Development of Antibacterial Countermeasures
Brian Kane · Spero Therapeutics (United States) · funded by National Institutes of Health
2021–2023 · contract · N01
Advanced Development of Antibacterial Countermeasures
Troy Lister · Spero Therapeutics (United States) · funded by National Institutes of Health
2021–2025 · contract · N01
Advanced Development of Antibacterial Countermeasures
Brian Kane · Spero Therapeutics (United States) · funded by National Institutes of Health
2021–2025 · contract · N01
Advanced Development of Antibacterial Countermeasures
Brian Kane · Spero Therapeutics (United States) · funded by National Institutes of Health
2021–2026 · contract · N01
Development of Therapeutic Products for Biodefense, AntiMicrobial Resistant (AMR) Infections and Emerging Infectious Diseases
Brian Kane · Spero Therapeutics (United States) · funded by National Institutes of Health
2021–2025 · contract · N01
Advanced Development of Antibacterial Countermeasures
Brian Kane · Spero Therapeutics (United States) · funded by National Institutes of Health
2021–2025 · contract · N01
Advanced Development of Antibacterial Countermeasures
Troy Lister · Spero Therapeutics (United States) · funded by National Institutes of Health
2021–2025 · contract · N01
Advanced Development of Antibacterial Countermeasures
Brian Kane · Spero Therapeutics (United States) · funded by National Institutes of Health
2021–2025 · contract · N01
Advanced Development of Antibacterial Countermeasures
Brian Kane · Spero Therapeutics (United States) · funded by National Institutes of Health
2021–2025 · contract · N01
Advanced Development of Antibacterial Resistance Countermeasures
Brian Kane · Spero Therapeutics (United States) · funded by National Institutes of Health
2017–2019 · research · R44
A Novel Gyrase Inhibitor for the Treatment of Drug-susceptible and Multidrug-resistant Mycobacterium tuberculosis Infections
Michael J Pucci · Spero Therapeutics (United States) · funded by National Institutes of Health
2017–2020 · research · R44
A Novel Gyrase Inhibitor for the Treatment of Drug-susceptible and Multidrug-resistant Mycobacterium tuberculosis Infections
Michael J Pucci · Spero Therapeutics (United States) · funded by National Institutes of Health
2015–2020 · contract · N01
Optimizing Lead Therapeutic Compounds Against Infectious Diseases
Michael J. Dawson · Spero Therapeutics (United States) · funded by National Institutes of Health